CV:PSYB PsyBio Therapeutics Corp

PsyBio Therapeutics Corp., a biotechnology company, develops formulations of psychoactive medications produced by genetically modified bacteria for the treatment of mental health and other disorders in the United States. It also engages in the research and development of naturally occurring tryptamines in varieties of hallucinogenic mushrooms, other tryptamines, phenethylamines, and combinations; and new molecular structures that do not occur in nature, which have therapeutics properties. The company is based in Coconut Creek, Florida.

This company cross-lists their shares on a U.S. stock exchange. See the related U.S. symbol PSYBF.

This company has cross-listed shares that trade in the U.S. as the symbol PSYBF.

0.08 CAD
As of 12/07/2022


Security Information
Category1:  Global Equity
Category2:  Common stocks
Category3:  Developed markets ex-US
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Canada
Country of incorporation:  
IPO date:  01/01/1900
Stock exchange:    TSX Venture Exchange
Exchange country:   Canada
Market cap:   8,607,300 CAD
Current dividend yield:   0.00%
Sedol:      

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy